Attenuated rapid onset vasodilation with greater force production in skeletal muscle of caveolin-2-/- mice.
Caveolin-2 (Cav2) is a major protein component of caveolae in membranes of vascular smooth muscle and endothelium, yet its absence alters the ultrastructure of skeletal muscle fibers. To gain insight into Cav2 function in skeletal muscle, we tested the hypothesis that genetic deletion of Cav2 would alter microvascular reactivity and depress contractile function of skeletal muscle in vivo. In the left gluteus maximus muscle (GM) of anesthetized Cav2(-/-) and wild-type (WT) male mice (age, 6 mo), microvascular responses to physiological agonists and to GM contractions were studied at 34°C. For feed arteries (FA), first- (1A), second- (2A) and third-order (3A) arterioles, respective mean diameters at rest (45, 35, 25, 12 μm) and during maximal dilation (65, 55, 45, 30 μm) were similar between groups. Cumulative dilations to ACh (10(-9) to 10(-5) M) and constrictions to norepinephrine (10(-9) to 10(-5) M) were also similar between groups, as were steady-state dilations during rhythmic twitch contractions (2 and 4 Hz; 30 s). For single tetanic contractions (100 Hz; 100, 250, and 500 ms), rapid onset vasodilation (ROV) increased with contraction duration throughout networks in GM of both groups but was reduced by nearly half in Cav2(-/-) mice compared with WT mice (P < 0.05). Nevertheless, maximal force during tetanic contraction was ∼40% greater in GM of Cav2(-/-) vs. WT mice (152 ± 14 vs. 110 ± 3 mN per square millimeter, respectively; P < 0.05). Thus, while structural and functional properties of resistance networks are well maintained in the GM of Cav2(-/-) mice, diminished ROV with greater force production reveals novel physiological roles for Cav2 in skeletal muscle.
Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, Missouri; and.
Charmain A
CA
Fernando
Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, Missouri; and.
Yajun
Y
Liu
Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, Missouri; and.
Grzegorz
G
Sowa
Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, Missouri; and Dalton Cardiovascular Research Center, Columbia, Missouri segalss@health.missouri.edu.
Steven S
SS
Segal
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D001158:Arteries / Q000187:drug effects / Q000503:physiopathology; D001160:Arterioles / Q000187:drug effects / Q000503:physiopathology*; D002081:Buttocks; D051243:Caveolin 2 / Q000235:genetics*; D000069416:Intravital Microscopy; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D055806:Microvessels / Q000187:drug effects / Q000503:physiopathology; D009119:Muscle Contraction; D018482:Muscle, Skeletal / Q000098:blood supply*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000503:physiopathology*; D009638:Norepinephrine / Q000494:pharmacology; D014655:Vascular Resistance; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014664:Vasodilation / Q000187:drug effects / Q000235:genetics*; D014665:Vasodilator Agents / Q000494:pharmacology
C495545:Cav2 protein, mouse; D051243:Caveolin 2; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D000109:Acetylcholine; D009638:Norepinephrine
arteriole; blood flow; exercise; feed artery; microcirculation